Jay Moorin - Net Worth and Insider Trading

Jay Moorin Net Worth

The estimated net worth of Jay Moorin is at least $18 Million dollars as of 2025-01-13. Jay Moorin is the 10% Owner of Achillion Pharmaceuticals Inc and owns about 2,663,854 shares of Achillion Pharmaceuticals Inc (ACHN) stock worth over $18 Million. Jay Moorin is the 10% Owner of Agile Therapeutics Inc and owns about 2,531 shares of Agile Therapeutics Inc (AGRX) stock worth over $3,822. Jay Moorin is also the Director of Novation Companies Inc and owns about 463,819 shares of Novation Companies Inc (NOVCQ) stock worth over $46. Details can be seen in Jay Moorin's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jay Moorin has not made any transactions after 2016-01-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jay Moorin

Jay Moorin Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jay Moorin owns 10 companies in total, including UroGen Pharma Ltd (URGN) , Eagle Pharmaceuticals Inc (EGRX) , and Agile Therapeutics Inc (AGRX) among others .

Click here to see the complete history of Jay Moorin’s form 4 insider trades.

Insider Ownership Summary of Jay Moorin

Ticker	Comapny	Transaction Date	Type of Owner
URGN	UroGen Pharma Ltd	2017-05-09	10 percent owner
EGRX	Eagle Pharmaceuticals Inc	2015-05-06	director & 10 percent owner
AGRX	Agile Therapeutics Inc	2016-01-27	10 percent owner
		2016-01-12	director
		2015-05-12	10 percent owner
		2011-04-04	10 percent owner
		2009-12-17	10 percent owner
		2006-05-03	director
		2005-11-29	10 percent owner
		2005-02-04	10 percent owner

Jay Moorin Latest Holdings Summary

Jay Moorin currently owns a total of 3 stocks. Among these stocks, Jay Moorin owns 2,663,854 shares of Achillion Pharmaceuticals Inc (ACHN) as of December 17, 2009, with a value of $18 Million and a weighting of 99.98%. Jay Moorin owns 2,531 shares of Agile Therapeutics Inc (AGRX) as of January 27, 2016, with a value of $3,822 and a weighting of 0.02%. Jay Moorin also owns 463,819 shares of Novation Companies Inc (NOVCQ) as of May 15, 2006, with a value of $46 and a weighting of 0%.

Latest Holdings of Jay Moorin

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ACHN	Achillion Pharmaceuticals Inc	2009-12-17	2,663,854	6.76	18,007,653
AGRX	Agile Therapeutics Inc	2016-01-27	2,531	1.51	3,822
NOVCQ	Novation Companies Inc	2006-05-15	463,819	0.00	46

Holding Weightings of Jay Moorin

Jay Moorin Form 4 Trading Tracker

According to the SEC Form 4 filings, Jay Moorin has made a total of 0 transactions in Achillion Pharmaceuticals Inc (ACHN) over the past 5 years. The most-recent trade in Achillion Pharmaceuticals Inc is the sale of 563,452 shares on December 17, 2009, which brought Jay Moorin around $2 Million.

According to the SEC Form 4 filings, Jay Moorin has made a total of 0 transactions in Agile Therapeutics Inc (AGRX) over the past 5 years. The most-recent trade in Agile Therapeutics Inc is the acquisition of 197 shares on January 27, 2016, which cost Jay Moorin around $3 Million.

According to the SEC Form 4 filings, Jay Moorin has made a total of 0 transactions in Novation Companies Inc (NOVCQ) over the past 5 years. The most-recent trade in Novation Companies Inc is the acquisition of 96,154 shares on May 15, 2006, which cost Jay Moorin around $3 Million.

Insider Trading History of Jay Moorin

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jay Moorin Trading Performance

GuruFocus tracks the stock performance after each of Jay Moorin's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jay Moorin is -7.79%. GuruFocus also compares Jay Moorin's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jay Moorin within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jay Moorin's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jay Moorin

Average Return

Average return per transaction

Outperforming Transactions

0 out of 2 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-6.59
Relative Return to S&P 500(%)	-6.84

Jay Moorin Ownership Network

Ownership Network List of Jay Moorin

No Data

Ownership Network Relation of Jay Moorin

Jay Moorin Owned Company Details

What does UroGen Pharma Ltd do?

Who are the key executives at UroGen Pharma Ltd?

Jay Moorin is the 10 percent owner of UroGen Pharma Ltd. Other key executives at UroGen Pharma Ltd include General Counsel Jason Drew Smith , Chief Medical Officer Mark Schoenberg , and Chief Financial Officer Dong Kim .

UroGen Pharma Ltd (URGN) Insider Trades Summary

Over the past 18 months, Jay Moorin made no insider transaction in UroGen Pharma Ltd (URGN). Other recent insider transactions involving UroGen Pharma Ltd (URGN) include a net sale of 25,590 shares made by Mark Schoenberg , and a net sale of 15,307 shares made by Jason Drew Smith .

In summary, during the past 3 months, insiders sold 0 shares of UroGen Pharma Ltd (URGN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 40,897 shares of UroGen Pharma Ltd (URGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 40,897 shares.

UroGen Pharma Ltd (URGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

UroGen Pharma Ltd Insider Transactions

No Available Data

What does Eagle Pharmaceuticals Inc do?

Who are the key executives at Eagle Pharmaceuticals Inc?

Jay Moorin is the director & 10 percent owner of Eagle Pharmaceuticals Inc. Other key executives at Eagle Pharmaceuticals Inc include director & President and CEO Scott Tarriff , EVP & Chief Commercial Officer Michael Shawn Moran , and Chief Medical Officer Judith Ng-cashin .

Eagle Pharmaceuticals Inc (EGRX) Insider Trades Summary

Over the past 18 months, Jay Moorin made no insider transaction in Eagle Pharmaceuticals Inc (EGRX). Other recent insider transactions involving Eagle Pharmaceuticals Inc (EGRX) include a net sale of 41,864 shares made by Scott Tarriff ,

In summary, during the past 3 months, insiders sold 0 shares of Eagle Pharmaceuticals Inc (EGRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 41,864 shares of Eagle Pharmaceuticals Inc (EGRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 41,864 shares.

Eagle Pharmaceuticals Inc (EGRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eagle Pharmaceuticals Inc Insider Transactions

No Available Data

What does Agile Therapeutics Inc do?

Who are the key executives at Agile Therapeutics Inc?

Jay Moorin is the 10 percent owner of Agile Therapeutics Inc. Other key executives at Agile Therapeutics Inc include Chief Financial Officer Scott M Coiante , Chief Commercial Officer Amy Welsh , and director & Chief Executive Officer Alfred Altomari .

Agile Therapeutics Inc (AGRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Agile Therapeutics Inc (AGRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Agile Therapeutics Inc (AGRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Agile Therapeutics Inc (AGRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Agile Therapeutics Inc Insider Transactions

No Available Data

What does Arno Therapeutics Inc do?

Who are the key executives at Arno Therapeutics Inc?

Jay Moorin is the director of Arno Therapeutics Inc. Other key executives at Arno Therapeutics Inc include other: See Footnote 1 S Donald Sussman , director & Secretary David M Tanen , and director & Chief Executive Officer & CMO Alexander A Zukiwski .

Arno Therapeutics Inc (ARNI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Arno Therapeutics Inc (ARNI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arno Therapeutics Inc (ARNI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Arno Therapeutics Inc (ARNI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arno Therapeutics Inc Insider Transactions

No Available Data

What does Immune Design Corp do?

Who are the key executives at Immune Design Corp?

Jay Moorin is the 10 percent owner of Immune Design Corp. Other key executives at Immune Design Corp include 10 percent owner & other: General Partner Column Group Gp, Lp , 10 percent owner Column Group L P , and 10 percent owner & other: General Partner Ponoi Management, Llc .

Immune Design Corp (IMDZ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Immune Design Corp (IMDZ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immune Design Corp (IMDZ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Immune Design Corp (IMDZ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immune Design Corp Insider Transactions

No Available Data

What does NovaDel Pharma Inc do?

Who are the key executives at NovaDel Pharma Inc?

Jay Moorin is the 10 percent owner of NovaDel Pharma Inc. Other key executives at NovaDel Pharma Inc include 10 percent owner Proquest Investments Ii Advisors Fund Lp , 10 percent owner Proquest Investments Ii Lp , and 10 percent owner Proquest Associates Ii Llc .

NovaDel Pharma Inc (NVDL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NovaDel Pharma Inc (NVDL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NovaDel Pharma Inc (NVDL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NovaDel Pharma Inc (NVDL)'s detailed insider trading history can be found in Insider Trading Tracker table.

NovaDel Pharma Inc Insider Transactions

No Available Data

What does Achillion Pharmaceuticals Inc do?

Who are the key executives at Achillion Pharmaceuticals Inc?

Jay Moorin is the 10 percent owner of Achillion Pharmaceuticals Inc. Other key executives at Achillion Pharmaceuticals Inc include EVP & Chief Commercial Officer Paul E Firuta , EVP & Chief Medical Officer Steven Zelenkofske , and General Counsel Martha E Manning .

Achillion Pharmaceuticals Inc (ACHN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Achillion Pharmaceuticals Inc (ACHN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Achillion Pharmaceuticals Inc (ACHN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Achillion Pharmaceuticals Inc (ACHN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Achillion Pharmaceuticals Inc Insider Transactions

No Available Data

What does Paratek Pharmaceuticals Inc do?

Who are the key executives at Paratek Pharmaceuticals Inc?

Jay Moorin is the director of Paratek Pharmaceuticals Inc. Other key executives at Paratek Pharmaceuticals Inc include CLO & General Counsel & Sec. William M. Haskel , President & Chief Commercial Adam Woodrow , and Chief Development & Regulatory Randall B. Brenner .

Paratek Pharmaceuticals Inc (PRTK) Insider Trades Summary

Over the past 18 months, Jay Moorin made no insider transaction in Paratek Pharmaceuticals Inc (PRTK). Other recent insider transactions involving Paratek Pharmaceuticals Inc (PRTK) include a net sale of 48,967 shares made by Evan Loh , a net sale of 34,526 shares made by William M. Haskel , and a net sale of 31,250 shares made by Michael Bigham .

In summary, during the past 3 months, insiders sold 0 shares of Paratek Pharmaceuticals Inc (PRTK) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 142,346 shares of Paratek Pharmaceuticals Inc (PRTK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 142,346 shares.

Paratek Pharmaceuticals Inc (PRTK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Paratek Pharmaceuticals Inc Insider Transactions

No Available Data

What does Palatin Technologies Inc do?

Who are the key executives at Palatin Technologies Inc?

Jay Moorin is the 10 percent owner of Palatin Technologies Inc. Other key executives at Palatin Technologies Inc include Executive Vice President & CFO Stephen T Wills , director & President and CEO Carl Spana , and director & Exec. VP Research and Devel. Perry B Molinoff .

Palatin Technologies Inc (PTN) Insider Trades Summary

Over the past 18 months, Jay Moorin made no insider transaction in Palatin Technologies Inc (PTN). Other recent insider transactions involving Palatin Technologies Inc (PTN) include a net sale of 9,997 shares made by Stephen T Wills , a net sale of 5,700 shares made by Deveer Robert K Jr , and a net sale of 200 shares made by Alan W Dunton .

In summary, during the past 3 months, insiders sold 0 shares of Palatin Technologies Inc (PTN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 21,897 shares of Palatin Technologies Inc (PTN) were sold and 6,000 shares were bought by its insiders, resulting in a net sale of 15,897 shares.

Palatin Technologies Inc (PTN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Palatin Technologies Inc Insider Transactions

No Available Data

What does Molecular Templates Inc do?

Who are the key executives at Molecular Templates Inc?

Jay Moorin is the 10 percent owner of Molecular Templates Inc. Other key executives at Molecular Templates Inc include 10 percent owner Biotech Target N V , Chief Medical Officer Maurizio Voi , and CFO & Treasurer Sean Mclennan .

Molecular Templates Inc (MTEM) Insider Trades Summary

Over the past 18 months, Jay Moorin made no insider transaction in Molecular Templates Inc (MTEM). Other recent insider transactions involving Molecular Templates Inc (MTEM) include a net purchase of 3,225,499 shares made by Biotech Target N V ,

In summary, during the past 3 months, insiders sold 1,279,820 shares of Molecular Templates Inc (MTEM) in total and bought 0 shares, with a net sale of 1,279,820 shares. During the past 18 months, 1,279,820 shares of Molecular Templates Inc (MTEM) were sold and 533,688 shares were bought by its insiders, resulting in a net sale of 746,132 shares.

Molecular Templates Inc (MTEM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Molecular Templates Inc Insider Transactions

No Available Data

Jay Moorin Mailing Address

Above is the net worth, insider trading, and ownership report for Jay Moorin. You might contact Jay Moorin via mailing address: C/o Proquest Investments, L.p, 2430 Vanderbilt Beach Road, #108 - 190, Naples Fl 34109.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.